Skip to main content

Table 4 Stratified Estimated Pointwise Cumulative Incidence of Loss to follow-up

From: Predictors of loss to follow-up among children on long-term antiretroviral therapy in Zambia (2003–2015)

 

3 months

Cumulative incidence % (95% CI)

6 months

Cumulative incidence % (95% CI)

1 year

Cumulative incidence % (95% CI)

3 years

Cumulative incidence % (95% CI)

5 years

Cumulative incidence % (95% CI)

10 years

Cumulative incidence % (95% CI)

p-value

Age at ART Initiation1

      

< 0.0001

< 1 year

5.0(2.5–8.9)

9.0(5.3–13.7)

14.7(9.9–2.0)

22.3(16.3–28.8)

25.9(19.4–32.8)

27.7(20.9–34.9)

 

1–5 years

3.6(2.0–5.8)

4.9(3.1–7.4)

7.6(5.2–10.5)

12.7(9.5–16.3)

14.8(11.3–18.8)

17.2(12.9–21.9)

6–15 years

1.3(0.5–2.6)

1.5(0.7–2.9)

2.1(1.1–3.8)

5.3(0.3.5–7.7)

10.0(7.3–13.3)

20.3(14.8–26.2)

Weight for Height z-score < −3SD at ART initiation2

0.01077

Yes

5.0(2.4–8.8)

7.2(4.0–11.6)

9.4(5.7–14.3)

16.6(11.4–22.6)

21.0(14.8–27.8)

NA

 

No

2.3(1.5–3.5)

3.4(2.3–4.8)

5.7(4.2–7.3)

9.8(7.9–12.1)

13.2(10.9–15.8)

20.1(16.3–24.1)

Regimen at Baseline3

      

< 0.0001

1NNRTI + 2NRTI’s

2.2(1.3–3.3)

3.2(2.2–4.5)

5.1(3.8–6.7)

8.6(6.9–10.6)

12.1(10.0–14.6)

19.0(15.3–23.0)

 

LPV/R

1.8(0.1–8.7)

5.6(1.4–14.1)

11.6(4.6–22.1)

30.5(17.0–45.2)

34.0(19.4–49.2)

43.9(20.6–65.2)

3NRTI

10.3(4.7–18.3)

12.9(6.5–21.4)

17.0(9.5–26.2)

27.5(18.0–37.9)

30.5(20.4–41.2)

N/A

Year of ART Initiation4

< 0.0001

2003–2005

0

0

0

0

2.8(0.5–8.8)

12.7(6.1–21.6)

 

2006–2009

2.9(1.7–4.7)

3.7(2.3–5.6)

5.9(4.1–8.2)

8.6(6.4–11.3)

12.2(9.5–15.2)

N/A

2010–2012

2.6(1.2–4.9)

4.3(2.4–7.0)

6.2(3.9–9.4)

14.9(11.1–19.2)

19.0(14.3–24.1)

N/A

2013–2015

4.0(1.6–8.0)

6.8(4.0–9.4)

11.5(6.8–17.4)

N/A

N/A

N/A

Access to Phone5

< 0.0001

Yes

2.6(1.6–3.9)

3.3(2.1–4.9)

4.6(3.2–6.3)

8.2(6.3–10.5)

10.9(8.6–13.5)

17.5(13.4–22.1)

 

No

3.3(1.7–5.6)

5.7(3.6–8.6)

10.1(7.1–13.7)

17.0(13.0–21.4)

22.4(17.7–27.3)

29.1(22.3–36.2)

HIV Disclosed at Baseline6

0.0266

Yes

0.5(0.04–2.7)

0.5(0.04–2.7)

0.5(0.04–2.7)

3.8(1.7–7.4)

7.0(3.8–11.5)

18.5(11.3–27.0)

 

No

3.3(2.3–4.7)

4.8(3.5–6.5)

7.7(6.0–9.6)

12.7(10.5–15.1)

16.4(13.8–19.2)

21.2(17.2–25.6)

  1. *Cumulative incidence estimates and confidence intervals derived from Fig. 2